- Home >
- Clinicals Trials >
- COLIBRI- 2
Retour à la liste des essais cliniquesCancers gynécologiques
COLIBRI- 2
Phase·Ib/II, multicenter, open-label study evaluating BDC-1001, a HER2-targeted TLR7/8 agonist antibody-drug conjugate, as monotherapy and in combination with nivolumab in advanced HER2-expressing solid tumors.
- Ouvert à Paris depuis le : 14/08/2025
- Ouvert à Saint-Cloud depuis le : 01/07/2025
- Public cible : Adult
- Phase : Phase II
Description de l'essai
Phase Ib (Dose-escalation):;Assess safety, dose-limiting toxicities (DLTs), and the maximum tolerated dose (MTD).;Identify the recommended Phase 2 dose (RP2D). ;cancernetwork.com;+3;targetedonc.com;+3;onclive.com;+3;Phase II (Expansion cohorts):;Evaluate efficacy, focusing on objective response rate (ORR) at the RP2D.
Investigateur principal
